J Tate Thigpen

Summary

Affiliation: University of Mississippi Medical Center
Country: USA

Publications

  1. ncbi request reprint Cisplatin as second-line therapy in ovarian carcinoma treated initially with single-agent paclitaxel: a Gynecologic Oncology Group study
    J Tate Thigpen
    Division of Oncology, Department of Medicine, University of Mississippi School of Medicine, Jackson, MS 39216 4505, USA
    Gynecol Oncol 90:581-6. 2003
  2. ncbi request reprint Cisplatin as initial chemotherapy in ovarian carcinosarcomas: a Gynecologic Oncology Group study
    J Tate Thigpen
    Department of Medicine, University of Mississippi School of Medicine, Jackson, MS 39216 4505, USA
    Gynecol Oncol 93:336-9. 2004
  3. ncbi request reprint Role of pegylated liposomal doxorubicin in ovarian cancer
    J Tate Thigpen
    Division of Oncology, Department of Medicine, University of Mississippi Medical Center, 2500 North State Street, Jackson, MS 39216, USA
    Gynecol Oncol 96:10-8. 2005
  4. ncbi request reprint Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study
    J Tate Thigpen
    Division of Oncology, Department of Medicine, University of Mississippi School of Medicine, Jackson, USA
    J Clin Oncol 22:3902-8. 2004
  5. ncbi request reprint Management of women who present with T4 breast cancer
    Galen V Poole
    Department of Surgery, Division of Oncology, University of Mississippi Medical Center, Jackson, Mississippi 39216, USA
    Am Surg 70:662-6; discussion 666-7. 2004

Collaborators

Detail Information

Publications5

  1. ncbi request reprint Cisplatin as second-line therapy in ovarian carcinoma treated initially with single-agent paclitaxel: a Gynecologic Oncology Group study
    J Tate Thigpen
    Division of Oncology, Department of Medicine, University of Mississippi School of Medicine, Jackson, MS 39216 4505, USA
    Gynecol Oncol 90:581-6. 2003
    ..Those patients who had persistent (stable) or progressive disease while receiving paclitaxel, or a recurrence of disease within 6 months of completing six cycles of paclitaxel therapy, received single-agent cisplatin...
  2. ncbi request reprint Cisplatin as initial chemotherapy in ovarian carcinosarcomas: a Gynecologic Oncology Group study
    J Tate Thigpen
    Department of Medicine, University of Mississippi School of Medicine, Jackson, MS 39216 4505, USA
    Gynecol Oncol 93:336-9. 2004
    ..The Gynecologic Oncology Group (GOG) initiated a concerted effort to study cytotoxic therapy for these cancers in 1976. This report presents data on cisplatin, the first of the agents to be studied in this disease...
  3. ncbi request reprint Role of pegylated liposomal doxorubicin in ovarian cancer
    J Tate Thigpen
    Division of Oncology, Department of Medicine, University of Mississippi Medical Center, 2500 North State Street, Jackson, MS 39216, USA
    Gynecol Oncol 96:10-8. 2005
    ..The plethora of agents currently available present difficult choices for physicians. The present effort seeks to examine the role of one of these agents, pegylated liposomal doxorubicin...
  4. ncbi request reprint Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study
    J Tate Thigpen
    Division of Oncology, Department of Medicine, University of Mississippi School of Medicine, Jackson, USA
    J Clin Oncol 22:3902-8. 2004
    ..This trial of stage III, IV, or recurrent disease evaluated whether combining these agents increases response rate (RR) and prolongs progression-free survival (PFS) and overall survival (OS) over doxorubicin alone...
  5. ncbi request reprint Management of women who present with T4 breast cancer
    Galen V Poole
    Department of Surgery, Division of Oncology, University of Mississippi Medical Center, Jackson, Mississippi 39216, USA
    Am Surg 70:662-6; discussion 666-7. 2004
    ..Multimodality therapy gives the best results, but early surgery may be required for progression of disease during chemotherapy or because of extensive ulceration at initial presentation...